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ABSTRACT
Introduction: This study is a European multicentre,
randomised, double-blind, placebo-controlled trial
investigating the efficacy and safety of nilvadipine as a
disease course modifying treatment for mild-to-
moderate Alzheimer’s disease (AD) in a phase III study
that will run for a period of 82 weeks with a treatment
period of 78 weeks.
Methods and analysis: Adult patients, males and
females over 50 years with mild-to-moderate AD as
defined by the National Institute of Neurological and
Communicative Disorders and Stroke/Alzheimer’s
disease and Related Disorders Association (NINCDS-
ADRDA) criteria, will be included in the study. It aims
to recruit a total of 500 patients with AD; 250 in the
nilvadipine group and 250 in the placebo group.
Participants will be randomised to receive nilvadipine,
an 8 mg overencapsulated, sustained release capsule,
or a matching overencapsulated placebo (sugar pill) for
a period of 78 weeks of treatment. The primary efficacy
outcome measure in this study is the change in
cognitive function as assessed by the Alzheimer’s
disease Assessment Scale (ADAS-Cog 12) from
baseline to the end of treatment duration (78 weeks).
There are two key secondary outcome measures, the
Clinical Dementia Rating Scale Sum of Boxes (CDR-sb)
and the Disability Assessment for Dementia (DAD). If a
statistically significant effect is seen in the primary
outcome, CDR-sb will be considered to be a coprimary
end point and only the DAD will contribute to the
secondary outcome analysis.
Ethics and dissemination: The study and all
subsequent amendments have received ethical approval
within each participating country according to national
regulations. Each participant will provide written
consent to participate in the study. All participants will
remain anonymised throughout and the results of the
study will be published in an international peer-
reviewed journal.
Trial registration number: EUDRACT Reference
Number: 2012-002764-27.
INTRODUCTION
The current disappointing state of clinical
trials aimed at advancing therapeutic inter-
ventions for Alzheimer’s disease (AD) has
necessitated the need for development of
novel strategies that target multiple aspects
of the pathogenic process in this neurode-
generative condition. Furthermore, ideally,
any novel drugs or compounds tested would
have a demonstrated safety profile in order
to expedite the path to clinical application.
Calcium antagonists or calcium channel
blockers (CCBs) were first introduced over
25 years ago as coronary vasodilators for the
treatment of coronary heart disease, and
have since achieved notable recognition in
the treatment of arterial hypertension.1
Nilvadipine (trade name: Nivadil), a dihydro-
pyridine (DHP) calcium channel antagonist,
Strengths and limitations of this study
▪ Large European multicentre double-blind, rando-
mised placebo-controlled trial.
▪ Investigator driven.
▪ Testing a repositioned medication with a proven
safety profile and approved for the treatment of
hypertension.
▪ Does not test the disease modifying efficacy and
safety of nilvadipine at the predementia stage.
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is currently licensed to treat patients with hypertension.2
However, recent research has highlighted other proper-
ties of certain CCBs, including nilvadipine, suggesting
that they are protective not just against stroke-related
dementia, but also independently against AD.3
Research to date has suggested that the AD preventive
effect of DHP CCBs, may not be mediated through their
antihypertensive effects, but rather via an anti-β-amyloid
(Aβ) mechanism where the accumulation of Aβ in the
brain is reduced by altering Aβ production in the brain
and Aβ clearance across the blood–brain barrier (BBB).
Paris et al investigated the effects of a number of com-
monly used antihypertensive DHPs and non-DHPs on
Aβ production both in vitro and in vivo and found that
not all DHPs are equal. Nilvadipine and amlodipine
were found to significantly lower Aβ40 as well as Aβ42
production in vitro, however, other DHPs and non-DHPs
had little effect or even increased Aβ40 and Aβ42 pro-
duction in vitro. The in vivo studies using transgenic
mouse models of AD (Tg PS1/APPsw) highlighted nilva-
dipine reduced levels of Aβ in the brain and, further-
more, nilvadipine enhanced Aβ clearance across the
BBB. In addition to these properties, nilvadipine has
shown efficacy against a broad range of AD pathological
mechanisms, including τ-phosphorylation, reduced cere-
bral blood flow and neuroinflammation.3
Studies have found that nilvadipine is distributed
extensively throughout the body, including the brain
and has been shown to have a cerebrocirculatory enhan-
cing effect.4 Nilvadipine has also been shown to protect
low-density lipoprotein cholesterol from in vivo oxidation
in patients with hypertension with high risk of athero-
sclerosis and to inhibit the generation of cytokines
derived from activated T lymphocytes in collagen
disease complicated with essential hypertension.5 6
Several epidemiological studies with different calcium
channel antagonists have been conducted to determine
their potential usefulness in the management of AD. In
the Systolic Hypertension in Europe (Syst-Eur) trial,
which involved active treatment with the DHP CCB
nitrendipine in over 2400 patients, there was a 55%
reduction in the incidence of AD.7 The Baltimore
Longitudinal Study of Ageing also found a strong trend
towards reduced relative risk of AD in patients treated
with DHP CCBs, with no lowered risk observed in the
non-DHP CCB treatment group.8
Furthermore, nilvadipine has been shown to have
favourable effects on cognitive function with stabilisation
of cognitive decline and reduced conversion to AD in
patients with hypertension with mild cognitive impair-
ment.9 A study by Kennelly et al10 provided preliminary
evidence suggesting the potential efficacy in the treat-
ment of AD. A 6-week open label study demonstrated
that nilvadipine was well tolerated in patients with AD.11
A nilvadipine slow release 8 mg formulation did not
reduce blood pressure (BP) in non-hypertensive patients
with AD, but appropriately lowered BP in hypertensive
cases. No patient started on nilvadipine requested or
required discontinuation of the medication throughout
this study, highlighting that nilvadipine is well tolerated
in patients with AD and has demonstrated safety as a
licensed antihypertensive treatment.
In summary, this study will investigate the safety and
efficacy of nilvadipine as a disease-modifying treatment
in patients with mild-to-moderate AD over a period of
18 months across nine countries in Europe including
Ireland, Germany, Greece, France, Holland, Hungary,
Italy, Sweden and the UK.
Overall, the aim is to build on the initial studies of nil-
vadipine as a treatment for AD by investigating its effi-
cacy and establish its safety profile in a phase III
double-blind, randomised, placebo-controlled trial.
METHODS AND ANALYSIS
Trial design
This is a multicentre, randomised, double-blind, placebo-
controlled study of nilvadipine compared with placebo.
Eligible patients will be randomly assigned to receive
8 mg of nilvadipine or placebo daily for 78 weeks of treat-
ment. Patients will initially undergo a screening assess-
ment to confirm eligibility. This will be followed by a
baseline visit (week 0), when each patient is randomised
and will receive the first dose of study medication.
Patients will then undergo assessments at weeks 6, 13, 26,
39, 52, 65 and 78 (±7 days) after beginning treatment.
A final follow-up assessment will be undertaken at
82 weeks (study end point).
Inclusion/exclusion criteria
Patients diagnosed with mild-to-moderate AD based on
the National Institute of Neurological and Communicative
Disorders and Stroke/Alzheimer’s disease and Related
Disorders Association, Inc (NINCDS-ADRDA) criteria are
suitable for treatment with nilvadipine.12 See box 1 for
details of study inclusion and exclusion criteria.
Randomisation and blinding
To prevent the introduction of bias, randomisation will be
via an online system, accessed via http://www.ctu.co.uk,
hosted by the Clinical Trials Unit (CTU), King’s College
London (KCL). Eligible participants will be randomised to
either the nilvadipine or placebo treatment group. The
nilvadipine capsules and placebo capsules will be pack-
aged and labelled identically. Randomisation will be at the
level of the individual patient, using block randomisation
with randomly varying block sizes and stratified by country
site. Once the patient has been randomised, the online
system will automatically recognise which treatment packs
are located in each study pharmacy at the recruiting study
site and will randomly select a pack in the appropriate trial
arm to be dispensed to the patient. All study staff at all
sites will be blinded to treatment allocation and will
remain blind until the end of the trial.
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Unblinding
Medtox, an Emergency Scientific and Medical Service,
(http://www.medtox.co.uk), will provide a 24 h emer-
gency unblinding service across all participating coun-
tries. Unblinding requests will only be granted in a
medical emergency and when requested by a physician.
This system will be available to any physician treating a
patient in the study, including out of hours general prac-
titioner (GP) services and hospital emergency depart-
ments. Details of the emergency service will be provided
to all participants at the baseline visit.
Recruitment
There are a total of 23 study sites in nine participating
European countries. Recruitment for the study will be
undertaken locally at each study site according to local
guidelines and procedures relevant to that site.
Screening
Once a patient has been identified and has expressed
an interest in participation, a screening assessment will
be arranged to determine eligibility. The screening
assessment consists of: (1) medical history and physical
Box 1 Inclusion and exclusion criteria
Inclusion criteria
▸ Males and females over age 50.
▸ Diagnosis of probable Alzheimer’s disease.
▸ Standardised Mini-Mental State Examination (SMMSE; Standish & Molloy, 1997) score of greater than or equal to 12 and less than 27.
▸ Patients on a stable dose (>3 months) of cholinesterase inhibitor or memantine.
▸ Fluency in relevant language sufficient to reliably complete all study assessments.
▸ Patients with blood pressure (BP) values greater than 100/65 mm Hg but less than 159/99 mm Hg using an office-based BP measure-
ment, or patients with BP values greater than 105/70 mm Hg but less than 140/90 mm Hg using an ambulatory BP measurement.19
▸ Patients who retain capacity will provide written informed consent for participation.
▸ Patients who are not on cholinesterase inhibitors or memantine due to poor tolerability and/or who will not require treatment with these
medications during the course of the study can be included.
Exclusion criteria
▸ Patients with comorbid dementia due to other neurological disorders such as Parkinson’s disease, vascular dementia, Huntington’s
disease, Pick’s disease, Creutzfeldt-Jakob disease, normal pressure hydrocephalus, brain tumour, progressive supranuclear palsy, seizure
disorder, subdural haematoma or multiple sclerosis, as well as patients with HIV disease, neurosyphilis, history of significant head
trauma with loss of consciousness followed by persistent neurological deficits, known structural brain abnormalities or any other condi-
tion known to interfere with cognitive function.
▸ Patients currently taking a calcium channel blockers (CCB) or β-blocker.
▸ Patients who, in the opinion of the investigator, have a medical condition that would preclude them from participating in the study, for
example, chronic heart failure, syncope within the past year, significant valvular heart disease, that is, severe aortic and mitral stenosis,
or symptomatic orthostatic hypotension within the last year.
▸ Patients with significant cardiovascular disease including recent history of acute myocardial infarction or unstable angina pectoris.
▸ Patients who in the opinion of the investigator are unlikely to complete the protocol due to care issues, etc.
▸ Current Axis I (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM IV)) diagnosis of schizophrenia, bipolar dis-
order or major depression.
▸ Patients who are currently or who have within the past year met criteria for drug or alcohol abuse or dependence.
▸ Pregnant women or women who may possibly become pregnant (premenopausal). Female patients must be postmenopausal (no
menses for ≥12 months without an alternative medical cause) to participate in the study.
▸ Female patients who are breast feeding.
▸ Patients with a history of hypersensitivity to nilvadipine (Nivadil).
▸ Patients who have taken an investigational or other unapproved drug during the 30 days or 5 half-lives, whichever is longer, prior to
baseline.
▸ Patients who are taking any excluded medications. Specific groups of medications are excluded in the trial, including CCB, β-blocker,
α-agonist and nitrates.
▸ Abnormal ECG results that, in the opinion of the clinician, prevent participation in the study.
▸ SMMSE score of less than 12 or greater than 26.
▸ Patients who are participating in other clinical research studies.
▸ Clinically significant laboratory blood test abnormality on his/her screening test.
▸ Significant renal impairment (estimated glomerular filtration rate: <30 mL/min).
▸ Severe hepatic impairment (liver cirrhosis).
▸ BP values less than 100/65 mm Hg or greater than 159/99 mm Hg using an office-based BP measurement or patients with BP values
less than 105/70 mm Hg or greater than 140/90 mm Hg using an ambulatory BP measurement.
▸ Patients with clinically significant abnormalities in their CT/MRI results, which would prevent inclusion in the study.
▸ The medical food stuff Souvenaid is under exclusion from the study.
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examination including neurological examination; (2)
confirmation of diagnosis of AD; (3) Standardised
Mini-Mental State Examination (SMMSE); (4) confirm-
ation that the patient is not on any excluded medica-
tions for the trial; (5) BP readings standing as well as
sitting; (6) ECG; (7) clinical laboratory tests including
full blood count, renal and liver function and (8) review
of CT/MRI report if undertaken in the past 4 years and
if available.
Once the screening assessment has been completed
and the patient is deemed eligible for trial participation,
the baseline visitation will be arranged and will take
place within 6 weeks of the screening assessment. The
patient’s GP will be notified in writing regarding the
patient’s participation and will also be provided with a
list of excluded trial medications (table 1).
Consenting process
Written consent for trial participation will be sought
from all potential participants following a full explan-
ation of the trial and its objectives, risks and potential
benefits. A patient information leaflet (PIL) and carer’s
information leaflet (CIL) will be provided at least 7 days
prior to obtaining written consent to allow participants
time to consider enrolling in the trial. Written consent
will be obtained from the patient as well as the carer at
the screening visit prior to the undertaking of any inter-
ventions or assessments. The carer will consent to
accompany the patient to assessments, supervise admin-
istration of the study drug and participate in certain
assessments requiring caregiver input.
The procedure for obtaining informed consent when
the participant has reduced decision-making capacity
will follow national law and will be assessed by the rele-
vant bodies in each of the participating countries.
Study medication
Trial drug dose and treatment duration
There is little published data regarding the efficacy of
nilvadipine to reduce the risk or improve the symptoms
of dementia in humans. As such, the dosage selection
for this study is based on the findings of Kennelly et al,
2011, and on findings from reports indicating benefit,
including increased cerebral blood flow, from standard
dosage antihypertensive medication.8 10 13–15 An 8 mg
enteric coated capsule will be used in the trial. The
Table 1 Excluded medications for NILVAD trial
CCB β-Blocker Nitrates α-Antagonists
Nifedipine Bisoprolol Amyl nitrate Prazosin
Nimodipine Atenolol Isosorbide dinitrate Doxazosin
Diltiazem Metoprolol Nitroglycerin Tamsulosin
Verapamil All other β-blockers Pentaerythyitol tetranitrate All other α-antagonists
Isradipine
All other CCB
Other agents/excluded agents
Warfarin
Dantrolene
Aprepitant
Erythromycin
Fluconazole
Anticonvulsants: phenytoin, carbamazepine
Medications that are not excluded but drug interactions are noted for:
Other vasodilators: nitroprusside and hydralazine. Monitor for risk of antihypertensive effect
Tricyclic Antidepressants: monitor for risk of antihypertensive effect.
Antiarrhythmics: amiodarone, quinidine and disopyramide. Monitor levels of quinidine
Digoxin: nilvadipine may increase plasma digoxin levels. Monitor digoxin levels
Ciclosporin: monitor ciclosporin levels with concomitant use with nilvadipine
Cytochrome P450 3A4 inhibitors: indinavir, nelfinavir, ritonavir, itraconazole, ketoconazole, voriconazole, posaconazole,
nefazodone, saquinavir, telithromycin and cimetidine. Nilvadipine is metabolised by CYP450 3 A4 and thus any agent that
inhibits this enzyme system may potentially cause elevated levels of nilvadipine in the plasma. All patients will be monitored
throughout, as per the study protocol, for any possible adverse drug interactions
Cytochrome P450 3A4 inducers: rifampicin, gemfibrozil and some antihyperglycaemics such as troglitazone. CPY450 3A4
inducers may potentially decrease the bioavailability of nilvadipine
Patients will be advised of the possible interaction with grapefruit juice (CPY450 3A4 inhibitor) and requested to avoid
taking the trial medication with it
This list is not exhaustive and therefore investigators should contact the sponsor’s medical advisor for clarification regarding
the acceptability and safety of these and other agents. All participants will be advised of potential interactions with other
medications and the GP will also be provided with the list of exclusionary and precautionary medications. Any patient
prescribed any of the above medications will be monitored closely throughout the study
CCB, calcium channel blockers; GP, general practitioner.
4 Lawlor B, et al. BMJ Open 2014;4:e006364. doi:10.1136/bmjopen-2014-006364
Open Access
matching placebo will consist of sugar pellets. The active
trial drug and placebo will both be overencapsulated
with a gelatin capsule.
Treatment with the trial drug will be for a duration of
78 weeks, based on statistical and power calculations
using the Alzheimer’s disease Assessment Scale–cogni-
tive subscale (ADAS-Cog 12) as the primary efficacy
outcome measure. This is the minimum duration of
treatment necessary to demonstrate a disease modifying
effect.
Dispensing of study medication
A treatment pack with a unique batch number, patient
identification number (PIN) and expiry date, containing
either the nilvadipine or placebo capsules, will be dis-
pensed to each participant at the baseline assessment
(week 0) and subsequently at weeks 13, 26, 39, 52 and 65.
Each pack will contain 98 capsules (a 13-week supply with 7
extra capsules). The first dose will be taken at the baseline
visit under observation. Thereafter, patients will take one
capsule daily after breakfast. The timing of the medication
is to reduce the risk of orthostatic hypotension.
Medication adherence will be monitored at each dis-
pensing time point. At each assessment participants will
be requested to return the used treatment packs and
any leftover capsules. Any excess capsules returned will
be recorded and patients will be counselled regarding
compliance when necessary. If a patient returns more
than 20 capsules the reasons for this must be recorded
and the site investigator informed.
Excluded medications
Specific medications have been excluded from use
during the trial to reduce the risk of adverse effects.
Namely, all other CCBs, β-blockers, α-blockers and
nitrates. Other specific medications excluded from use
during the trial include warfarin, dantrolene, anticonvul-
sants such as phenytoin, carbamazepine, phenobarbital
and all moderate-to-potent cytochrome P450 3A4
inhibitors.
The GP for each patient will be provided with a
detailed list of the excluded medications and requested
not to prescribe any, if possible, for the duration of the
trial (table 1). If treatment with an excluded medication
is indicated and prescribed during the trial, the partici-
pant will become ineligible and trial participation will be
terminated.
Trial assessment schedule
Following the screening assessment to determine eligibil-
ity, all participants will have a total of nine assessments
throughout the trial, a baseline assessment (week 0) fol-
lowed by assessments at weeks 6, 13, 26, 39, 52, 65 and 78
(±7 days), with a study end point assessment at week 82.
The baseline assessment will consist of: (1) concomitant
medications check; (2) weight and height check; (3)
ADAS-Cog; (4) Clinical Dementia Rating Scale Sum of
Boxes (CDR-sb); (5) Disability Assessment for Dementia
(DAD) and (6) BP measurements (sitting and standing).
At all subsequent visits, the following assessments will
be carried out: (1) concomitant medications check; (2)
adverse events check; (3) BP measurements (sitting and
standing) and (4) medication compliance check.
In addition, at weeks 13, 52 and 78, cognitive assessments
will be undertaken, the ADAS-Cog CDR-sb and DAD.
Furthermore, at week 78 participants will undergo
repeat weight and height check, physical examination
and clinical laboratory blood test. The study medication
will also terminate at this point.
At week 82, participants will undergo their final assess-
ment where they will be asked if they experienced any
adverse events after finishing the trial medication
(figure 1 and table 2).
Termination of trial participation
Scheduled termination of participation in the trial will
occur once a patient has completed the week 82 assess-
ment (study end point assessment).
Unscheduled terminations may occur if a participant
chooses to withdraw from the study at any time. Each
participant has the right to withdraw at any time without
providing a reason. Participants may also be removed
from the study based on treatment discontinuation criteria:
see box 2. All such cases will be discussed with the trial
physician and may result in patient withdrawal from the
study, if this is deemed necessary on patient safety
grounds. If a site is considering removing a participant
from the study, this must be discussed with the Principal
Investigator (PI) and the Project Coordinator before the
participant is withdrawn.
STATISTICS
Sample size calculation
The total number of participants is based on the power
calculation computed on the primary efficacy parameter,
ADAS-Cog 12, as follows: the primary variable of the
study is a continuous response variable—the ADAS-Cog
12 score—from independent control (ie, placebo) and
experimental participants (ie, treatment) with one
control per experimental participant. In previous studies
the change in ADAS-Cog score was normally distributed
with a mean score of 7 and SD of 11 for the placebo
group and with a mean score of 3.5 and SD of 9 for the
experimental group.16 To observe such a difference
between the two groups, 175 experimental participants
and 175 control participants must be recruited to be
able to reject the null hypothesis that the population
means of the experimental and control groups are equal
with a probability (power) of 0.9. The type I error prob-
ability associated with this test of this null hypothesis is a
two sided 0.05. To account for an attrition rate of 30%,
the total sample size per group is 250. Since the power
calculation assumes a 50% smaller decline in the experi-
mental group compared with the placebo group for the
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ADAS-Cog, we could make the same assumption for the
CDR-sb. If used as a single primary end point, the
CDR-sb has similar power to the ADAS-Cog, because,
historically, the mean to SD ratio is very similar between
these two outcomes, and because we are assuming a
fixed percentage effect relative to placebo. So if we
assume independence of the two outcomes, which each
have a 90% probability of success, then the probability
of succeeding on both primary outcomes is
0.9*0.9=0.81, indicating that the power for achieving
both outcomes simultaneously is more than 80%. As the
change from baseline on the ADAS-Cog and CDR-sb are
somewhat correlated, this is a conservative estimate of
the power for this study to be pivotal.
The primary and key secondary efficacy analyses will
use a mixed-model repeated measures analysis for the
change from baseline, including data from all postbase-
line visits, with terms for baseline score, site and treat-
ment group. The linear contrasts on the LS-Means of
the treatment effects will be used to perform the
between-group comparisons. The primary and key sec-
ondary statistical analyses will be performed once, after
data collection has been halted and the database has
been finalised. No interim analyses will be performed.
Figure 1 NILVAD trial flow
chart.
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Primary analysis
The primary analyses will consist of a gatekeeper
approach with the following stages:
1. First, the p value for between-group comparison of
the ADAS-Cog outcome will be compared with 0.05.
If significance is achieved, then the study will be con-
sidered a successful proof of concept study for effi-
cacy. If significance is not achieved the secondary
analyses will proceed.
2. Second, if significance is achieved in step 1, then the
p value for the between-group comparison of the
CDR-sb outcome will be compared with 0.05. If sig-
nificance is achieved, then the study will be consid-
ered a successful pivotal study for efficacy. If
significance is not achieved the secondary analyses
will proceed.
3. Third, if significance is achieved in steps 1 and 2,
then an analysis will be undertaken using time as a
continuous numerical variable, on ADAS-Cog. The
same analysis will be undertaken on CDR-sb. The
between-group comparison of slopes will be evaluated
for statistical significance at α=0.05. If significance is
achieved in both of these measures, then the study
will have provided evidence of a delay of disability. If
significance is achieved in neither the secondary ana-
lyses will proceed.
In the case of step 1 of the primary analysis not achiev-
ing statistical significance, steps 2 and 3 will still be per-
formed, but any significant outcomes will be for
discussion purposes only.T
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Box 2 Study discontinuation criteria
1. Adverse experience related to the trial drug.
2. Intercurrent illness.
3. The request of the participant, his/her legal representative,
investigator or sponsor, whether for administrative or other
reasons.
4. Non-compliance with medication, protocol violation or unreli-
able behaviour.
5. Patients who develop symptomatic elevated blood pressure
(BP; greater than 159/99 mm Hg using office-based BP mea-
surements or greater than 140/90 mm Hg using ambulatory
blood pressure monitoring (ABPM)) or symptomatic lowered
BP (less than 100/65 mm Hg with office-based BP measure-
ments or less than 105/70 mm Hg with ABPM), which fails to
be controlled with medication.
6. Patients who develop symptomatic orthostatic hypotension
with symptoms including a syncopal episode (but not a
seizure), recurrent unexplained falls, intolerant orthostatic
hypotensive symptoms, defined as recurrent presyncopal
symptoms interfering with daily functioning.
7. Patients who develop persistent or severe symptoms possibly
related to treatment with nilvadipine, such as a persistent
headache interfering with daily functioning, severe peripheral
oedema or any other symptoms considered to be related to
treatment with nilvadipine.
Lawlor B, et al. BMJ Open 2014;4:e006364. doi:10.1136/bmjopen-2014-006364 7
Open Access
The primary statistical analysis will be carried out on
the intent-to-treat population, which will include all ran-
domised patients. For the intention-to-treat secondary
analyses, all data from patients who are terminated or
withdrawn from the study will be held and analysed.
Where possible, even if patients are withdrawn from the
study medication, follow-up data collection will continue
as scheduled.
Secondary analysis
The above analysis will be conducted on the DAD
measure to assess change in functional capacity between
groups in the intention-to-treat population. Patients will
be classified as ‘responders’ if a change in an outcome
score is observed from baseline to 78 weeks, which is less
than half of the expected decline in the placebo group
over that time span. For example, on the ADAS-Cog
measure this corresponds to a change of −3.5 or higher
for classification as ‘responder’. A Cochran-Mantel-
Haenszel (CMH) χ2 test will be used to compare the
proportions of responders between the treatment
groups, stratified by country.
The above analyses will be repeated on the ‘per proto-
col population’ (those participants who have no viola-
tions to the protocol for the duration of the study).
Safety analysis
Safety analysis will include descriptive statistics for all
randomised participants.
Outcome measures
The primary outcome measure is the change from base-
line to week 78 in cognitive function, as assessed by the
ADAS-Cog 12. There are two secondary outcome mea-
sures, the CDR-sb and the DAD. If a statistically signifi-
cant effect is seen in the primary outcome, CDR-sb will
be considered to be a coprimary end point and only the
DAD will contribute to the secondary outcome analysis.
Trial data management system
All the patient data generated from the trial will be
recorded online via an electronic case report form
(eCRF), on an online Macro System, prepared and run
by the CTU, KCL, and will be accessible to all study sites
via http://www.ctu.co.uk. A unique PIN will be gener-
ated for each patient once they are registered on the
system at the time of screening and this will be used to
identify them throughout the trial.
In addition, the CTU will send each study site ‘source
data worksheets’, to be printed by the study sites and
used to record all patient data, from screening through
to the end of the trial. A paper file containing the hard
copies of all the relevant patient documentation and
‘source data worksheets’ will be opened for each partici-
pant at each study site.
Study site staff will be given unique usernames and
passwords to access this system for data entry. Data must
be entered, where possible, on the system within 7 days
of data collection.
Study monitors in each country will be issued with
unique usernames and passwords to access the system
for monitoring. Each participating country will have a
study monitor who will be responsible for overview and
monitoring of trial activities at each study site within
each country, including maintenance of the trial master
file, site pharmacy files and site investigator file. Site PIs
will be given unique usernames and passwords to access
the online system with particular PI privileges, specific-
ally the ability to place an eSignature on each patient’s
eCRF at the end of the trial to confirm the data set for
the patient is complete.
Trial management
The day-to-day management of the trial will be coordi-
nated through the scientific project manager at
St James’s Hospital, Dublin, the sponsor site. An investi-
gators’ meeting will be held once a year and key PI from
each of the partner countries will be in attendance.
ETHICS AND DISSEMINATION
The study will be conducted according to Good Clinical
Practice (GCP) guidelines and in accordance with the
Declaration of Helsinki.
Regarding safety considerations, the risk associated
with the trial is low. Nilvadipine is a licensed medication
for high BP in several European countries including
Ireland, Germany, France, Spain, Portugal and the UK
and it has a reliable safety profile. A successful short-
term safety study was carried out on patients with AD in
2008, which showed very good tolerability in this patient
population over the 6-week trial period.11
Patient safety monitoring will be assessed by physical
examination, clinical laboratory tests and serial BP mea-
surements. Physical examination and routine laboratory
blood tests will be undertaken at the screening visit. A
routine evaluation of general health and well-being will
be conducted at baseline and at all subsequent visits also.
BP measurements will be carried out at each visit. For
any patient who develops elevated BP during the study
or who presents with elevated BP at screening, add on
therapy with a non-centrally acting ACE inhibitor will be
considered in consultation with the trial clinician and
the patient’s GP.
All adverse events will be assessed and reported, includ-
ing: Adverse Events or Adverse Experiences (AE);
Adverse Drug Reactions (ADR); Unexpected Adverse
Drug Reactions (UAR); Serious Adverse Events (SAE) or
Serious Adverse Reactions (SAR); and Suspected
Unexpected SAR (SUSAR).
Additional safety measurements may be conducted
more frequently if clinically indicated or at the discretion
of the site investigator. The reason for any additional
safety measurements will be recorded in the eCRF.
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A Data Management and Safety Monitoring Board
(DMSB) has been established to which all SAE will be
reported. The DMSB consists of a statistician and three
clinicians, one of whom will act as the chair of the
DMSB. The DMSB will meet on a 6 monthly basis and
will review and monitor blinded data exported from the
eCRF system and the randomisation system (KCL), these
data will be sent to the trial statistician who will prepare
reports on data and safety monitoring.
Dissemination
It is intended that all positive, neutral or negative results
from the trial will be published in international peer
reviewed journals. Authorship and publication will be as
per the agreed study publication policy.
DISCUSSION
AD is an ever-increasing public health concern among
the ageing population and is the most common form of
dementia, affecting more than 15 million individuals
worldwide and around 5 million Europeans. The direct
and indirect costs of AD and other dementias amount to
more than €440 000 million each year.17 It is estimated
that by 2050, 1 in 85 of the population worldwide will
have AD and that approximately 40% of these cases will
need the level of care equivalent to a nursing home.
Even modest therapeutic advances that lead to small
delays in Alzheimer’s onset and progression could signifi-
cantly reduce the global and European burden of the
disease and the level of care required by patients. While
there are symptomatic-based drug therapies such as cho-
linesterase inhibitors and glutamate antagonists available
for AD, these medications do not stop the disease process
or prevent neuronal degeneration. Therefore there is a
clear unmet medical and public health need for the
development of new treatments and it is imperative that
the scientific community strive to discover disease modify-
ing treatments that can be introduced at the earliest pos-
sible stage of neurodegeneration.18
There is convincing scientific evidence for an antiamy-
loid effect of nilvadipine, with reduced Aβ production,
enhanced Aβ clearance from the brain and improved
cortical perfusion in mouse models of AD, highlighting
potential disease modifying benefits.3 This study will
help to establish if such disease modifying effects will be
evident in human subjects also.
Research to date has shown that nilvadipine has a
good safety profile and is well tolerated in patients with
AD, facilitating the inclusion of older adults with a range
of comorbidities in this study and the results from this
study will provide further information about the efficacy
and safety of Nilvadipine in patients with AD.
If this trial is successful, nilvadipine would represent a
significant advance in the treatment and management
of patients with AD and would have a major impact on
the health and social care costs incurred in Europe by
this neurodegenerative disorder.
Trial status
Enrollment for the trial began in May 2013 and the
recruitment period will continue until December 2014.
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